The purpose of the study is to identify optimally effective dose of whole-cell, heat-killed Mycobacterium vaccae formulated as a pill and consequently carry out multi-country, placebo-controlled, randomized Phase III trial in patients with drug-sensitive, multi-drug resistant (MDR-TB) and TB-HIV.